EDIT logo

EDIT
Editas Medicine Inc

17,042
Mkt Cap
$293.62M
Volume
589,893.00
52W High
$4.54
52W Low
$1.29
PE Ratio
-1.59
EDIT Fundamentals
Price
$2.91
Prev Close
$3.00
Open
$2.94
50D MA
$2.59
Beta
2.02
Avg. Volume
1.8M
EPS (Annual)
-$1.80
P/B
10.76
Rev/Employee
$465,747.13
$111.99
Loading...
Loading...
News
all
press releases
Editas Medicine (NASDAQ:EDIT) Stock Passes Above Fifty Day Moving Average - Here's Why
Editas Medicine (NASDAQ:EDIT) Shares Pass Above Fifty Day Moving Average - Time to Sell...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Editas Medicine (NASDAQ:EDIT) Share Price Passes Above 50 Day Moving Average - Here's What Happened
Editas Medicine (NASDAQ:EDIT) Stock Passes Above Fifty Day Moving Average - Should You Sell...
MarketBeat·9d ago
News Placeholder
Why Is Black Diamond (BDTX) Up 19.3% Since Last Earnings Report?
Black Diamond (BDTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·16d ago
News Placeholder
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Recommendation of "Moderate Buy" from Analysts
Shares of Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) have received an average rating of "Moderate Buy" from the eight brokerages that are covering the firm, MarketBeat reports. One analyst...
MarketBeat·19d ago
News Placeholder
Editas Medicine (NASDAQ:EDIT) Downgraded by Wall Street Zen to Sell
Wall Street Zen cut Editas Medicine from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat·21d ago
News Placeholder
Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·23d ago
News Placeholder
Zacks Research Weighs in on Editas Medicine FY2028 Earnings
Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Analysts at Zacks Research issued their FY2028 earnings estimates for Editas Medicine in a note issued to investors on Monday, March 23rd. Zacks...
MarketBeat·1mo ago
News Placeholder
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Rating of "Moderate Buy" from Analysts
Shares of Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eight analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have...
MarketBeat·1mo ago
News Placeholder
Is Editas Medicine Going to $0?
Key PointsEditas Medicine has been on fire over the trailing-12-month period...
Nasdaq News: Markets·1mo ago
News Placeholder
Editas Medicine Details In Vivo CRISPR Plan, Targets Year-End Human Proof-of-Concept for EDIT-401
Editas Medicine (NASDAQ:EDIT) executives outlined the company's in vivo CRISPR gene-editing strategy and near-term clinical plans during a recent discussion featuring President and CEO Gilmore...
MarketBeat·2mo ago
<
1
2
...
>

Latest EDIT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.